JP7236737B2 - 抗ａｐｏｅ抗体 - Google Patents

抗ａｐｏｅ抗体 Download PDF

Info

Publication number
JP7236737B2
JP7236737B2 JP2019523734A JP2019523734A JP7236737B2 JP 7236737 B2 JP7236737 B2 JP 7236737B2 JP 2019523734 A JP2019523734 A JP 2019523734A JP 2019523734 A JP2019523734 A JP 2019523734A JP 7236737 B2 JP7236737 B2 JP 7236737B2
Authority
JP
Japan
Prior art keywords
seq
antibody
apoe
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019523734A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020506162A (ja
JP2020506162A5 (enExample
Inventor
デイビッド・ホルツマン
ホン・ジャン
ファン・リャオ
トゥ・ガ・ビエン－リー
マーク・エス・デニス
ジン・グオ
アダム・ピー・シルバーマン
ライアン・ジェイ・ワッツ
イン・ジャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis WUSTL
Original Assignee
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University in St Louis WUSTL filed Critical Washington University in St Louis WUSTL
Publication of JP2020506162A publication Critical patent/JP2020506162A/ja
Publication of JP2020506162A5 publication Critical patent/JP2020506162A5/ja
Priority to JP2022164847A priority Critical patent/JP2022191397A/ja
Application granted granted Critical
Publication of JP7236737B2 publication Critical patent/JP7236737B2/ja
Priority to JP2024193660A priority patent/JP2025023998A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2019523734A 2016-10-28 2017-10-27 抗ａｐｏｅ抗体 Active JP7236737B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022164847A JP2022191397A (ja) 2016-10-28 2022-10-13 抗ａｐｏｅ抗体
JP2024193660A JP2025023998A (ja) 2016-10-28 2024-11-05 抗ａｐｏｅ抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662414413P 2016-10-28 2016-10-28
US62/414,413 2016-10-28
US201762533336P 2017-07-17 2017-07-17
US62/533,336 2017-07-17
PCT/US2017/058874 WO2018081642A1 (en) 2016-10-28 2017-10-27 Anti-apoe antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022164847A Division JP2022191397A (ja) 2016-10-28 2022-10-13 抗ａｐｏｅ抗体

Publications (3)

Publication Number Publication Date
JP2020506162A JP2020506162A (ja) 2020-02-27
JP2020506162A5 JP2020506162A5 (enExample) 2021-02-04
JP7236737B2 true JP7236737B2 (ja) 2023-03-10

Family

ID=62024064

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019523734A Active JP7236737B2 (ja) 2016-10-28 2017-10-27 抗ａｐｏｅ抗体
JP2022164847A Pending JP2022191397A (ja) 2016-10-28 2022-10-13 抗ａｐｏｅ抗体
JP2024193660A Pending JP2025023998A (ja) 2016-10-28 2024-11-05 抗ａｐｏｅ抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022164847A Pending JP2022191397A (ja) 2016-10-28 2022-10-13 抗ａｐｏｅ抗体
JP2024193660A Pending JP2025023998A (ja) 2016-10-28 2024-11-05 抗ａｐｏｅ抗体

Country Status (6)

Country Link
US (4) US11124562B2 (enExample)
EP (1) EP3532034A4 (enExample)
JP (3) JP7236737B2 (enExample)
AU (2) AU2017350947B2 (enExample)
CA (1) CA3042236A1 (enExample)
WO (1) WO2018081642A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022191397A (ja) * 2016-10-28 2022-12-27 ワシントン・ユニバーシティ 抗ａｐｏｅ抗体

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220296707A1 (en) * 2019-06-04 2022-09-22 Regents Of The University Of Minnesota Anti-opioid compounds and methods of making and using same
CN112538113B (zh) * 2020-08-06 2023-07-21 武汉天德生物科技有限公司 杂交瘤细胞株ace8及其产生的apoe4点突变单克隆抗体
EP4204003A4 (en) * 2020-08-28 2024-08-21 Board of Regents, The University of Texas System ANTIBODIES SPECIFIC TO CCL21 AND METHODS OF USE
EP4286406A4 (en) 2021-01-29 2025-07-23 Illimis Therapeutics Inc FUSION MOLECULE WITH NON-INFLAMMATORY PHAGOCYTOSIS-INDUCING ACTIVITY
WO2023069892A1 (en) * 2021-10-19 2023-04-27 Short Jay M Conditionally active proteins for neurodegenerative diseases
WO2025049995A1 (en) * 2023-09-01 2025-03-06 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Anti-ly6 antibodies and uses thereof
WO2025219956A1 (en) 2024-04-18 2025-10-23 Comed Therapeutics Ltd. Compositions and methods for rna delivery to cells
CN118184783B (zh) * 2024-05-09 2024-07-09 成都微芯新域生物技术有限公司 Hla-g抗体及其制备方法和用途
CN119147750A (zh) * 2024-11-15 2024-12-17 科美诊断技术股份有限公司 一种apoe4的光激化学发光检测试剂、试剂盒及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008502311A (ja) 2003-11-28 2008-01-31 アストラゼネカ アーベー 抗体
WO2013168174A1 (en) 2012-05-08 2013-11-14 Ramot At Tel-Aviv University Ltd. Apoe4 antibodies for treatment of neurodegenerative conditions
JP2014502276A (ja) 2010-12-02 2014-01-30 ワシントン・ユニバーシティ アミロイドプラーク関連症状の治療のための組成物及び方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US6313089B1 (en) 1997-08-20 2001-11-06 Duke University Complexes of apolipoprotein E and ciliary neurotrophic factor (CNTF) and methods of use
KR100767146B1 (ko) * 2000-02-24 2007-10-15 워싱톤 유니버시티 Ａβ 펩티드를 격리시키는 인간화 항체
WO2001072307A1 (en) * 2000-03-29 2001-10-04 The J. David Gladstone Institutes Methods of treating cognitive decline disease conditions with androgens
US7754433B2 (en) * 2001-12-03 2010-07-13 Amgen Fremont Inc. Identification of high affinity molecules by limited dilution screening
GB0200757D0 (en) * 2002-01-15 2002-02-27 Univ Manchester Diagnostic methods
CA2672049C (en) 2006-12-08 2016-05-10 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against angptl3
DE102009047243A1 (de) * 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien
US9102717B2 (en) * 2010-03-01 2015-08-11 The J. David Gladstone Institutes Antibody specific for apolipoprotein and methods of use thereof
JP2014511174A (ja) * 2011-02-07 2014-05-15 ネオトープ バイオサイエンシーズ リミテッド Ａｐｏｅ免疫療法
CA2859808A1 (en) 2011-12-19 2013-06-27 The Washington University Methods for diagnosing alzheimer's disease
US20150140672A1 (en) 2011-12-19 2015-05-21 Washington University Methods for detecting amyloid beta amyloidosis
CA2890758A1 (en) 2012-11-20 2014-05-30 Washington University Methods of diagnosing amyloid pathologies using analysis of amyloid-beta enrichment kinetics
WO2015187992A2 (en) * 2014-06-05 2015-12-10 The Regents Of The University Of Colorado, A Body Corporate Map44 polypeptides and constructs based on natural antibodies and uses thereof
US20170218058A1 (en) 2016-01-28 2017-08-03 Alector, LLC Anti-apoe4 antigen-binding proteins and methods of use thereof
US11124562B2 (en) * 2016-10-28 2021-09-21 Washington University Anti-ApoE antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008502311A (ja) 2003-11-28 2008-01-31 アストラゼネカ アーベー 抗体
JP2014502276A (ja) 2010-12-02 2014-01-30 ワシントン・ユニバーシティ アミロイドプラーク関連症状の治療のための組成物及び方法
WO2013168174A1 (en) 2012-05-08 2013-11-14 Ramot At Tel-Aviv University Ltd. Apoe4 antibodies for treatment of neurodegenerative conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J Neurosci., 2014 MAY 21, vol. 34, no. 21, pp. 7281-7292

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022191397A (ja) * 2016-10-28 2022-12-27 ワシントン・ユニバーシティ 抗ａｐｏｅ抗体

Also Published As

Publication number Publication date
EP3532034A4 (en) 2020-12-02
JP2020506162A (ja) 2020-02-27
US11124562B2 (en) 2021-09-21
JP2025023998A (ja) 2025-02-19
EP3532034A1 (en) 2019-09-04
AU2024203123A1 (en) 2024-05-30
US20220411485A1 (en) 2022-12-29
US11926660B2 (en) 2024-03-12
AU2017350947B2 (en) 2024-02-15
US20190270794A1 (en) 2019-09-05
US20240309077A1 (en) 2024-09-19
JP2022191397A (ja) 2022-12-27
AU2017350947A1 (en) 2019-05-16
US20250145697A1 (en) 2025-05-08
CA3042236A1 (en) 2018-05-03
WO2018081642A1 (en) 2018-05-03

Similar Documents

Publication Publication Date Title
JP7236737B2 (ja) 抗ａｐｏｅ抗体
US12145988B2 (en) Anti-TREM-2 agonist antibodies
JP7348987B2 (ja) ピログルタメートアミロイド－βに対する抗体及びその使用
CN107847595B (zh) 特异性针对过度磷酸化τ蛋白的抗体及其使用方法
US20150315267A1 (en) A method of reducing brain amyloid plaques using anti-ab antibodies
JP7475687B2 (ja) ヒトｈｍｇｂ１に特異的に結合するヒトモノクローナル抗体、及びそれを含有するアルツハイマー病を治療又は予防するための医薬組成物
JPWO2018030405A1 (ja) Ｈｍｇｂ１に対する抗体、及びそれを含有するアルツハイマー病を治療又は予防するための組成物
US20200385461A1 (en) Fusion constructs and uses thereof
WO2024155891A2 (en) Lilrb4/ilt3 antagonist compositions and methods of use thereof
CN120858110A (zh) 用抗Aβ抗体治疗神经病症的方法
WO2023247312A1 (en) Anti-transthyretin (ttr) binding proteins and uses thereof
WO2022124247A1 (ja) 前頭側頭葉変性症の予防又は治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201026

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201026

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20201026

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210813

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210824

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221013

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221013

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20221025

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221122

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221129

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230220

R150 Certificate of patent or registration of utility model

Ref document number: 7236737

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150